AR065670A1 - Combinacion de metformina r-(+) lipoato y agentes antihiperlipidemicos para el tratamiento de hiperglucemia diabetica y complicaciones diabeticas - Google Patents
Combinacion de metformina r-(+) lipoato y agentes antihiperlipidemicos para el tratamiento de hiperglucemia diabetica y complicaciones diabeticasInfo
- Publication number
- AR065670A1 AR065670A1 ARP080100977A ARP080100977A AR065670A1 AR 065670 A1 AR065670 A1 AR 065670A1 AR P080100977 A ARP080100977 A AR P080100977A AR P080100977 A ARP080100977 A AR P080100977A AR 065670 A1 AR065670 A1 AR 065670A1
- Authority
- AR
- Argentina
- Prior art keywords
- diabetic
- lipoate
- metformin
- treatment
- pharmaceutical composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Diabetes (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Composiciones farmacéuticas, métodos y kits, que comprenden metformina R-(+) lipoato y un agente antihiperlipidémico o una sal, hidrato, solvato y prodroga derivada de la misma farmacéuticamente aceptable para el tratamiento de hiperglucemiadiabética Tipo 2 y las complicaciones diabéticas. Reivindicacion 1: Una composicion farmacéutica caracterizada porque comprende metformina R-(+) lipoato [MR-(+)LA], y un inhibidor reductasa HMG-CoA o una sal aceptable en términos farmacéuticos,hidrato, solvato o un profármaco derivado de estos. Reivindicacion 7: La composicion farmacéutica de la reivindicacion 4 caracterizada porque el inhibidor reductasa HMG-CoA es atorvastatina cálcica. Reivindicacion 14: La composicion farmacéuticade la reivindicacion 3 caracterizada porque el inhibidor reductasa HMG-CoA es simvastatina, o una sal de esta aceptable en términos farmacéuticos. Reivindicacion 23: La composicion farmacéutica de la reivindicacion 22, caracterizada porque elinhibidor de absorcion de colesterol es ezetimibe, o una sal aceptable en términos farmacéuticos, hidrato, solvato y un profármaco derivado de éste.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US90599007P | 2007-03-09 | 2007-03-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR065670A1 true AR065670A1 (es) | 2009-06-24 |
Family
ID=39760278
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP080100977A AR065670A1 (es) | 2007-03-09 | 2008-03-07 | Combinacion de metformina r-(+) lipoato y agentes antihiperlipidemicos para el tratamiento de hiperglucemia diabetica y complicaciones diabeticas |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP2134169A2 (es) |
AR (1) | AR065670A1 (es) |
CL (1) | CL2008000684A1 (es) |
TW (1) | TW200901959A (es) |
WO (1) | WO2008112166A2 (es) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009085223A1 (en) * | 2007-12-20 | 2009-07-09 | Indigene Pharmaceuticals, Inc. | Combination of metformin r-(+)-lipoate and antihyperglycemic agents for the treatment of diabetic hyperglycemia and diabetic complications |
WO2012073256A1 (en) * | 2010-11-29 | 2012-06-07 | Cadila Healthcare Limited | Salts of rosuvastatin |
WO2015001568A2 (en) * | 2013-07-01 | 2015-01-08 | Laurus Labs Private Limited | Sitagliptin lipoate salt, process for the preparation and pharmaceutical composition thereof |
US10166246B2 (en) | 2014-05-27 | 2019-01-01 | City Of Hope | TGR5 agonist complexes for treating diabetes and cancer |
JP2021534208A (ja) * | 2018-08-24 | 2021-12-09 | エスペリオン・セラピューティクス・インコーポレイテッドEsperion Therapeutics, Inc. | 高コレステロール関連疾患について処置されている患者において糖尿病のリスクを低減させる方法 |
Family Cites Families (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2513251A (en) | 1947-06-21 | 1950-06-27 | Allied Chem & Dye Corp | Preparation of pyridine carboxylic acids |
GB860303A (en) | 1958-06-20 | 1961-02-01 | Ici Ltd | Pharmaceutical compositions comprising ª‡-aryloxy-aliphatic carboxylic acids and/or ª |
US3308020A (en) | 1961-09-22 | 1967-03-07 | Merck & Co Inc | Compositions and method for binding bile acids in vivo including hypocholesteremics |
US3674836A (en) | 1968-05-21 | 1972-07-04 | Parke Davis & Co | 2,2-dimethyl-{11 -aryloxy-alkanoic acids and salts and esters thereof |
FI52570C (fi) | 1969-04-16 | 1977-10-10 | Sumitomo Chemical Co | Menetelmä veren kolesteroli- tai lipoidipitoisuutta alentavien fenoxia lifaattisten karboksyylihappoyhdisteiden ja -esteriyhdisteiden valmist amiseksi. |
US3692895A (en) | 1970-09-08 | 1972-09-19 | Norman A Nelson | Method of reducing hypercholesteremia in humans employing a copolymer of polyethylenepolyamine and a bifunctional substance, such as epichlorohydria |
DE2230383C3 (de) | 1971-10-01 | 1981-12-03 | Boehringer Mannheim Gmbh, 6800 Mannheim | Phenoxyalkylcarbonsäurederivate und Verfahren zur Herstellung derselben |
US3948973A (en) | 1972-08-29 | 1976-04-06 | Sterling Drug Inc. | Halocyclopropyl substituted phenoxyalkanoic acids |
US4205064A (en) | 1973-06-11 | 1980-05-27 | Merck & Co., Inc. | Bile acid sequestering composition containing poly[{alkyl-(3-ammoniopropyl)imino}-trimethylenedihalides] |
JPS5612114B2 (es) | 1974-06-07 | 1981-03-18 | ||
JPS5522636A (en) | 1978-08-04 | 1980-02-18 | Takeda Chem Ind Ltd | Thiazoliding derivative |
ES8101585A1 (es) | 1980-02-15 | 1980-12-16 | Especialidades Farmaco Terape | Procedimiento de obtencion de un nuevo compuesto antiateros-clerotico |
DK149080C (da) | 1980-06-06 | 1986-07-28 | Sankyo Co | Fremgangsmaade til fremstilling af derivater af ml-236b-carboxylsyre |
US4342771A (en) | 1981-01-02 | 1982-08-03 | Pfizer Inc. | Hypoglycemic 5-substituted oxazolidine-2,4-diones |
US4367234A (en) | 1980-07-28 | 1983-01-04 | Pfizer Inc. | Hypoglycemic 5-substituted oxazolidine-2,4-diones |
US4617312A (en) | 1983-01-17 | 1986-10-14 | Pfizer Inc. | Aldose reductase inhibiting 5-(2-alkoxyphenyl) thiazolidinediones |
AR240698A1 (es) | 1985-01-19 | 1990-09-28 | Takeda Chemical Industries Ltd | Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales |
HU210339B (en) | 1985-05-21 | 1995-03-28 | Pfizer | Process for preparing thiazolidinediones and their pharmaceutical compositions haring hypoglycemic effect |
US4895723A (en) | 1986-09-08 | 1990-01-23 | Amer And Company | Cholestyramine compositions and method for preparation thereof |
JP2569746B2 (ja) | 1987-08-20 | 1997-01-08 | 日産化学工業株式会社 | キノリン系メバロノラクトン類 |
US5268181A (en) | 1989-04-13 | 1993-12-07 | Upsher-Smith Laboratories, Inc. | Method of using niacin to control nocturnal cholesterol synthesis |
US5126145A (en) | 1989-04-13 | 1992-06-30 | Upsher Smith Laboratories Inc | Controlled release tablet containing water soluble medicament |
AU1886892A (en) | 1991-04-12 | 1992-11-17 | Schering Corporation | Bicyclic amides as inhibitors of acyl-coenzyme a: cholesterol acyl transferase |
ATE195716T1 (de) | 1992-04-22 | 2000-09-15 | Ligand Pharm Inc | Retinoid-x rezeptor selektive verbindungen |
US6746691B2 (en) | 1993-09-20 | 2004-06-08 | Kos Pharmaceuticals, Inc. | Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique biopharmaceutical characteristics |
US5631365A (en) | 1993-09-21 | 1997-05-20 | Schering Corporation | Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents |
EP0882029B1 (en) | 1996-02-02 | 2003-04-02 | Merck & Co., Inc. | Heterocyclic derivatives as antidiabetic and antiobesity agents |
WO1997028149A1 (en) | 1996-02-02 | 1997-08-07 | Merck & Co., Inc. | Method for raising hdl cholesterol levels |
EP0904079B1 (en) | 1996-02-02 | 2004-03-24 | Merck & Co., Inc. | Antidiabetic agents |
ES2202582T3 (es) | 1996-02-02 | 2004-04-01 | MERCK & CO., INC. | Agentes antidiabeticos. |
EP1011651B1 (en) | 1996-02-02 | 2005-04-27 | Merck & Co., Inc. | Method of treating diabetes and related disease states |
US6203785B1 (en) | 1996-12-30 | 2001-03-20 | Geltex Pharmaceuticals, Inc. | Poly(diallylamine)-based bile acid sequestrants |
US6469035B1 (en) | 1997-07-31 | 2002-10-22 | Eugenio A. Cefali | Methods of pretreating hyperlipidemic individuals with a flush inhibiting agent prior to the start of single daily dose nicotinic acid therapy to reduce flushing provoked by nicotinic acid |
TW438784B (en) | 1997-08-29 | 2001-06-07 | Ssp Co Ltd | Triazole derivative or salt thereof and pharmaceutical composition for treating mycosis containing the same |
US6197786B1 (en) | 1998-09-17 | 2001-03-06 | Pfizer Inc | 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines |
US6294163B1 (en) | 1998-10-02 | 2001-09-25 | Geltex Pharmaceuticals, Inc. | Polymers containing guanidinium groups as bile acid sequestrants |
US6271264B1 (en) | 1998-12-01 | 2001-08-07 | Geltex Pharmaceuticals, Inc. | Polymers containing spirobicyclic ammonium moieties as bile acid sequestrants |
US6190649B1 (en) | 1999-04-23 | 2001-02-20 | Geltex Pharmaceuticals, Inc. | Polyether-based bile acid sequestrants |
FR2796551B1 (fr) | 1999-07-23 | 2003-07-25 | Lipha | Nouveaux sels de metformine, leur procede d'obtention et les compositions pharmaceutiques en renfermant |
CO5271716A1 (es) | 1999-11-30 | 2003-04-30 | Pfizer Prod Inc | Cristales de 4- carboxamino 1,2,3,4-tetrahidroquinolina 2- sustituida |
HN2000000203A (es) | 1999-11-30 | 2001-06-13 | Pfizer Prod Inc | Procedimiento para la obtencion de 1,2,3,4-tetrahidroquinolinas 4-carboxiamino-2- sustituidas. |
ES2401598T3 (es) | 2000-04-10 | 2013-04-22 | Teva Pharmaceutical Industries, Ltd. | Composiciones farmacéuticas estables que contienen ácidos 7-sustituido-3,5-dihidroxiheptanoicos o ácidos 7-sustituido-3,5-dihidroxiheptenoicos |
JP2004513112A (ja) | 2000-10-31 | 2004-04-30 | チバ スペシャルティ ケミカルズ ホールディング インコーポレーテッド | フルバスタチンナトリウムの結晶形 |
AU2002219175A1 (en) | 2000-12-21 | 2002-07-01 | Ciba Speciality Chemicals Holding Inc. | Crystalline forms of cerivastatin sodium |
SI20848A (sl) | 2001-03-14 | 2002-10-31 | Lek, Tovarna Farmacevtskih In Kemijskih Izdelkov, D.D. | Farmacevtska formulacija, ki vsebuje atorvastatin kalcij |
US6693094B2 (en) * | 2001-03-22 | 2004-02-17 | Chrono Rx Llc | Biguanide and sulfonylurea formulations for the prevention and treatment of insulin resistance and type 2 diabetes mellitus |
RU2265010C2 (ru) | 2001-04-30 | 2005-11-27 | Пфайзер Продактс Инк. | Промежуточные соединения для ингибиторов cetp и способы их получения |
US20030220301A1 (en) | 2002-02-14 | 2003-11-27 | Sonus Pharmaceuticals, Inc. | Metformin salts of lipophilic acids |
WO2004050037A2 (en) | 2002-12-04 | 2004-06-17 | Agennix Incorporated | Lactoferrin in the reduction of circulating cholesterol, vascular inflammation, atherosclerosis and cardiovascular disease |
WO2004089918A1 (ja) * | 2003-04-09 | 2004-10-21 | Japan Tobacco Inc. | 複素芳香5員環化合物及びその医薬用途 |
ZA200508932B (en) * | 2003-06-06 | 2007-03-28 | Takeda Pharmaceutical | Solid pharmaceutical preparation |
US20060089374A1 (en) * | 2003-07-17 | 2006-04-27 | Glenn Cornett | Enantiomeric compositions of cicletanine, alone and in combination with other agents, for the treatment of disease |
US7019022B2 (en) | 2003-12-15 | 2006-03-28 | Merck Frosst Canada & Co. | Substituted tetrahydrocarbazole and cyclopentanoindole derivatives |
-
2008
- 2008-03-07 CL CL200800684A patent/CL2008000684A1/es unknown
- 2008-03-07 WO PCT/US2008/003094 patent/WO2008112166A2/en active Application Filing
- 2008-03-07 AR ARP080100977A patent/AR065670A1/es unknown
- 2008-03-07 TW TW097108037A patent/TW200901959A/zh unknown
- 2008-03-07 EP EP08726603A patent/EP2134169A2/en not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
CL2008000684A1 (es) | 2008-08-01 |
WO2008112166A2 (en) | 2008-09-18 |
WO2008112166A3 (en) | 2008-10-30 |
TW200901959A (en) | 2009-01-16 |
EP2134169A2 (en) | 2009-12-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR067030A2 (es) | Composiciones farmaceuticas | |
DOP2006000269A (es) | Derivados de 4-amino-pirrolotriazina sustituida útiles para el tratamiento de trastornos hiper-proliferativos y enfermedades asociadas con la angiogénesis | |
ECSP077980A (es) | Inhibidores de la actividad akt | |
CR9018A (es) | Composiciones fungicidas | |
GT200800184A (es) | Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa-iv para el tratamiento o prevencion de diabetes. | |
ATE428411T1 (de) | Hdl-verstärkende kombinationstherapie-komplexe | |
AR065670A1 (es) | Combinacion de metformina r-(+) lipoato y agentes antihiperlipidemicos para el tratamiento de hiperglucemia diabetica y complicaciones diabeticas | |
BRPI0507198A (pt) | derivados de bisariluréia | |
BRPI0717907A2 (pt) | "composto, composição farmacêutica, métodos para tratar um câncer, para inbir ou modular a atividade da lipídeo quinase, processo para a produçãoo de uma composição farmacêutica, uso de um composto e kit" | |
WO2006119283A3 (en) | Anti-odor compositions and therapeutic use | |
ECSP066653A (es) | Derivados de bencenosulfonilamino-piridin-2-il y compuestos relacionados como inhibidores de 11-beta-hidroxiesteroide deshidrogenasa tipo 1(ii-beta-hsd-1) para el tratamiento de la diabetes y de la obesidad | |
ECSP067043A (es) | Derivados de pirrolotriazina útiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogénesis | |
MX2009000657A (es) | Composiciones y metodos para el tratamiento de mucositis. | |
MX2009005308A (es) | Composiciones que comprenden peroxido de benzoilo, al menos un derivado del acido naftoico y al menos un compuesto del tipo polimeros de poliuretano o derivados de estos y sus usos. | |
PA8627601A1 (es) | Hidrocloruro de [4-(5-aminometil-2-fluoro-fenil)-piperidin-1-ilo]-(4-bromo-3-metil-5-propoxi-tiofen-2-ilo)-metanona hidrocloruro como un inhibidor de triptasa de mastocitos | |
BRPI0617655A2 (pt) | composto ou um sal farmaceuticamente aceitável do mesmo, ou um isômero óptico do mesmo, uso de um composto, e, formulação farmacêutica | |
CR9425A (es) | Asociacion entre la ferroquina y un derivado de artemisinina para el tratamiento del paludismo | |
BRPI0515261A (pt) | composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, uso do composto quìmico ou de qualquer um de seus isÈmeros ou de qualquer mistura de seus isÈmeros, ou um sal farmaceuticamente aceitável do mesmo, e, método para o tratamento, a prevenção ou o alìvio de uma doença ou de um distúrbio ou de uma condição de um corpo de animal vivo | |
ECSP099483A (es) | Combinación de un inhibidor de desacetilasa de histona y un antimetabolito | |
BRPI0518448A2 (pt) | composiÇÕes farmacÊuticas compreendendo um derivado de camptotecina | |
EA201401042A1 (ru) | ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ И КОМБИНИРОВАННОЕ ЛЕКАРСТВЕННОЕ СРЕДСТВО, СОДЕРЖАЩЕЕ ИНГИБИТОРЫ HMG-CoA-РЕДУКТАЗЫ И ФОСФОДИЭСТЕРАЗЫ 4, И ИХ ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ ВОСПАЛИТЕЛЬНЫХ ЗАБОЛЕВАНИЙ ЛЕГКИХ | |
BRPI0620345A2 (pt) | composto, composição farmacêutica, uso de um composto, e, métodod para o tratamento de uma doença | |
BRPI0507859A (pt) | uso dos inibidores da colinesterase | |
AR039664A1 (es) | Composicion farmaceutica que comprende un inhibidor de lipasa y glucomanan | |
CL2007000485A1 (es) | Sal de alisquereno; procedimiento de preparacion; composicion farmaceutica que comprende a dicha sal; y uso del compuesto para el tratamiento de enfermedades que puedan ser moduladas mediante la inhibicion de la renina. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |